Recent Publications

• Vora J, Heise T.
• Variability of glucose-lowering effect as a limiting factor in optimising basal insulin therapy. A review.
• DIABETES OBES METAB. Accepted manuscript online: 1 MAR 2013 06:08PM EST | DOI: 10.1111/dom.12087
• Heise T, Seewald-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Wörle HJ.
• Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 week´s treatment with empagliflozin once daily in patients with type 2 diabetes.
• DIABETES OBES METAB. 2013 Jan 28. doi: 10.1111/dom.12073.[Epub ahead of print]
• Kapitza C, Forst T, Cöster HV, Poitiers F, Ruus P, Hincelin-Mery A.
• Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
• DIABETES OBES METAB. 2013 Jan 31. doi: 10.1111/dom.12076. [Epub ahead of print]
• Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, HeiseT.
• Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
• DIABETES OBES METAB. 15(1):77-83, 2013
• Arnolds S, Heckermann S, Koch C, Heissmann N, Sawicki PT.
• How do patients' Exp Clin Endocrinol Diabetespreferences compare to the present spectrum of diabetes research?
• EXP CLIN ENDOCRINOL DIABETES 121(1): 60-63, 2013
• Zijlstra E, Heise T, Nosek L, Heinemann L, Heckermann S.
• Continuous glucose monitoring: quality of hypoglycaemia detection.
• DIABETES OBES METAB 15(2):130-135, 2013
• Barkai L, Gurieva I, Stirban A, Tesfaye S, Czupryniak L, Mankovsky BN, Spallone V, Veresiu IA, Schnell O, Kempler P.
• Microvascular complications in children and adolescents with type 1 diabetes.
• DIABETES, STOFFWECHSEL UND HERZ 21: 309-315, 2012
• Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, HeiseT, Becker RH
• Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
• DIABETES CARE 35(12): 2626 – 2630, 2012
• Buehlmeier J, Frings-Meuthen P, Remer T, Maser-Gluth C, Stehle P, Biolo G, Heer M.
• Alkaline salts to counteract bone resorption and protein wasting induced by high salt intake: Results of a randomized controlled trial.
• J CLIN ENDOCRINOL METAB. 97(12): 4789-4797, 2012
• Caduff A, Heinemann L, Talary MS, Di Benedetto G, Lutz HU, Theander S.
• A 4-h hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects.
• ACTA DIABETOLOGIA 49(5):333-339, 2012
• Facchinetti A, Sparacino G, Guerra S, Luijf M, De Vries JH, Mader JK, Ellmerer M, Benesch C, Heinemann L, Bruttomesso D, Avogaro A, Cobelli C.
• Real-time improvement of continuous glucose-monitoring accuracy: the smart sensor concept.
• DIABETES CARE PMID: 23172973 (Epub ahead of print), 2012
• Heise T; Merker L, Matthaei S.
• Insulin degludec: Ein neues, ultra-langwirksames Basalinsulin.
• DIABETES, STOFFWECHSEL UND HERZ 21: 231-238, 2012
• Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H.
• Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
• DIABETES OBES METAB. 14(10): 944-950, 2012
• Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H.
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
• DIABETES OBES METAB 14(9): 859-864, 2012
• Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
• Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
• DIABETES RES CLIN PRACT. 97(2): 258-266, 2012
• Luijf YM, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader JK, De Vries JH.
• Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center.
• J DIABETES SCI TECHNOL. 6(5): 1103-1106, 2012
• McVey E, Hirsch L, Sutter DE, Kapitza C, Dellweg S, Clair J, Rebrin K, Judge K, Pettis RJ.
• Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
• J DIABETES SCI TECHNOL. 6(4):743-754, 2012
• Meier JJ, Pennartz C, Schenker N, Menge BA, Schmidt WE, Heise T, Kapitza C, Veldhuis JD.
• Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
• DIABETES OBES METAB. PMID: 23039360 (Epub ahead of print), 2012
• Morgan JL, Zwart SR, Heer M, Ploutz-Snyder R, Ericson K, Smith SM.
• Bone metabolism and nutritional status during 30-day head-down tilt bed rest.
• J APPL PHYSIOL. 113(10):1519-1529, 2012
• Nosek L, Cardot JM, Owens DR, Ibarra P, Bagate K, Vergnault G, Kaiser K, Fischer A, Heise T.
• Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
• DIABETES OBES METAB. 14(12):1137-1144, 2012
• Plum L, Lin HV, Aizawa K, Liu Y, Wardlaw SL, Accili D.
• InsR/FoxO1 signaling curtails hypothalamic POMC neuron number.
• PLoS ONE 7: e31487, 2012
• Rauch T, Graefe-Mody U, Deacon CF, Ring A, Holst JJ, Woerle HJ, Dugi KA, Heise T.
• Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
• DIABETES THER. 3(1):10.1007/s13300-012-0010-y [doi]
• Ren H, Orozco IJ, Su Y, Suyama S, Gutiérrez-Juárez R, Horvath TL, Wardlaw SL, Plum L, Arancio O, Accili D.
• FoxO1 target Gpr17 activates AgRP neurons to regulate food intake.
• CELL 149(6): 1341–1326, 2012
• Smith SM, Heer M, Wang Z, Huntoon CL, Zwart SR.
• Long-duration space flight and bed rest effects on testosterone and other steroids.
• JCEM 97(1):270-8, 2012
• Smith SM, Heer M, Shackelford L, Sibonga JD, Ploutz-Snyder L, Zwart SR.
• Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry.
• J BONE MINER RES. 27(9):1896-906, 2012
• Stirban A, Dellweg S.
• Neue Methoden zur Diagnose mikrovaskulärer Komplikationen.
• DIABETES CONGRESS REPORT 5: 22-25, 2012
• Stirban A, Nandrean S, Kirana S, Götting C, Veresiu IA, Tschoepe D.
• Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
• MED. doi:10.1155/2012/968761, 2012
• Stirban A, Kotsi P, Franke K, Strijowski U, Cai W, Götting C, Tschoepe D.
• Acute macrovascular dysfunction in patients with type 2 diabetes mellitus induced by ingestion of advanced glycated betalactoglobulins.
• DIABETES CARE doi: 10.2337/dc12-1489, 2012
• Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, Heise T, Heinemann L, Roden M, Schloot NC.
• Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
• PLoS One 7(3):e33108, 2012
• Thomas A, Heinemann L.
• Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study.
• J DIABETES SCI TECHNOL. 6(3): 572-580, 2012
• Zwart SR, Gibson CR, Mader TH, Ericson K, Heer M, Smith SM.
• Vision changes after spaceflight are related are related to alterations in folate- and vitamin B-12 dependent one-carbon metabolism.
• J NUTR. 142(3): 427-31, 2012
• Heer M.
• An analysis of the effect of olibra: a 12-week randomized control trial and a review of earlier studies.
• J DIABETES SCI TECHNOL 6(3): 709-711, 2012
• Tigges C, Heer M.
• The second-meal effect: can meal-skipping and nutrient composition of a meal affect postprandial blood glucose levels from a subsequent meal?
• DIABET NUTRITJE RISK CARDIOMETABOLIC 3: 33-39, 2012
• Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A.
• für die Arbeitsgruppe CGM der Arbeitsgemeinschaft Diabetologische Technologie der DDG (AGDT) Evidenz und Konsens für den klinischen Einsatz von CGM.
• DIABETES, STOFFWECHSEL UND HERZ 1: 32-47, 2012
• Stirban A, Nandrean S, MD, Kirana S, Christian Götting C, Andrei Veresiu IA, Tschoepe D.
• Benfotiamine counteracts smoking induced vascular dysfunction in healthy smokers.
• INT J VASC MED, Volume 2012, Article ID 968761, doi:10.1155/2012/968761

Home